FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361960904> ?p ?o ?g. }

• W4361960904 abstract "<div>Abstract<p><b>Purpose:</b> Rigosertib, a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K), and gemcitabine have synergistic antitumor activity when combined in preclinical studies. This phase I study aimed to determine the recommended phase II dose (RPTD) of the combination of rigosertib and gemcitabine in patients with cancer.</p><p><b>Experimental Design:</b> Patients with solid tumors who failed standard therapy or were candidates for gemcitabine-based therapy were eligible. Gemcitabine was administered on days 1, 8, and 15 on a 28-day cycle and rigosertib on days 1, 4, 8, 11, 15, and 18. Pharmacokinetic studies were conducted during an expansion cohort of patients with advanced pancreatic ductal adenocarcinoma (PDA).</p><p><b>Results:</b> Forty patients were treated, 19 in the dose-escalation phase and 21 in the expansion cohort. Dose levels evaluated were (gemcitabine/rigosertib mg/m²): 750/600 (<i>n</i> = 4), 750/1,200 (<i>n</i> = 3), 1,000/600 (<i>n</i> = 3), 1,000/1,200 (<i>n</i> = 3), and 1,000/1,800 (<i>n</i> = 6 + 21). One dose-limiting toxicity (death) occurred at the highest dose level (1,000/1,800) tested. Non–dose-limiting ≥grade II/III toxicities included neutropenia, lymphopenia, thrombocytopenia, fatigue, and nausea. Grade III/IV neutropenia, thrombocytopenia, and fatigue were seen in two, one, and two patients in the expansion cohort. Partial responses were observed in PDA, thymic cancer, and Hodgkin lymphoma, including gemcitabine-pretreated PDA. The pharmacokinetic profile of rigosertib was not affected by gemcitabine.</p><p><b>Conclusion:</b> The RPTD established in this study is rigosertib 1,800 mg/m² and gemcitabine 1,000 mg/m². This regimen is well tolerated with a toxicity profile of the combination similar to the profile of gemcitabine alone. Antitumor efficacy was observed in patients who previously progressed on gemcitabine-based therapy. <i>Clin Cancer Res; 18(7); 2048–55. ©2012 AACR</i>.</p></div>" @default.
• W4361960904 created "2023-04-05" @default.
• W4361960904 creator A5007992309 @default.
• W4361960904 creator A5008479914 @default.
• W4361960904 creator A5021339333 @default.
• W4361960904 creator A5022146508 @default.
• W4361960904 creator A5025469479 @default.
• W4361960904 creator A5025646273 @default.
• W4361960904 creator A5026482426 @default.
• W4361960904 creator A5033199189 @default.
• W4361960904 creator A5041114807 @default.
• W4361960904 creator A5048907012 @default.
• W4361960904 creator A5078259926 @default.
• W4361960904 date "2023-03-31" @default.
• W4361960904 modified "2023-09-27" @default.
• W4361960904 title "Data from Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer" @default.
• W4361960904 doi "https://doi.org/10.1158/1078-0432.c.6519816" @default.
• W4361960904 hasPublicationYear "2023" @default.
• W4361960904 type Work @default.
• W4361960904 citedByCount "0" @default.
• W4361960904 crossrefType "posted-content" @default.
• W4361960904 hasAuthorship W4361960904A5007992309 @default.
• W4361960904 hasAuthorship W4361960904A5008479914 @default.
• W4361960904 hasAuthorship W4361960904A5021339333 @default.
• W4361960904 hasAuthorship W4361960904A5022146508 @default.
• W4361960904 hasAuthorship W4361960904A5025469479 @default.
• W4361960904 hasAuthorship W4361960904A5025646273 @default.
• W4361960904 hasAuthorship W4361960904A5026482426 @default.
• W4361960904 hasAuthorship W4361960904A5033199189 @default.
• W4361960904 hasAuthorship W4361960904A5041114807 @default.
• W4361960904 hasAuthorship W4361960904A5048907012 @default.
• W4361960904 hasAuthorship W4361960904A5078259926 @default.
• W4361960904 hasConcept C121608353 @default.
• W4361960904 hasConcept C126322002 @default.
• W4361960904 hasConcept C184235292 @default.
• W4361960904 hasConcept C185592680 @default.
• W4361960904 hasConcept C2780210213 @default.
• W4361960904 hasConcept C2780258809 @default.
• W4361960904 hasConcept C55493867 @default.
• W4361960904 hasConcept C71924100 @default.
• W4361960904 hasConcept C98274493 @default.
• W4361960904 hasConceptScore W4361960904C121608353 @default.
• W4361960904 hasConceptScore W4361960904C126322002 @default.
• W4361960904 hasConceptScore W4361960904C184235292 @default.
• W4361960904 hasConceptScore W4361960904C185592680 @default.
• W4361960904 hasConceptScore W4361960904C2780210213 @default.
• W4361960904 hasConceptScore W4361960904C2780258809 @default.
• W4361960904 hasConceptScore W4361960904C55493867 @default.
• W4361960904 hasConceptScore W4361960904C71924100 @default.
• W4361960904 hasConceptScore W4361960904C98274493 @default.
• W4361960904 hasLocation W43619609041 @default.
• W4361960904 hasOpenAccess W4361960904 @default.
• W4361960904 hasPrimaryLocation W43619609041 @default.
• W4361960904 hasRelatedWork W1570579653 @default.
• W4361960904 hasRelatedWork W1906345089 @default.
• W4361960904 hasRelatedWork W1989631932 @default.
• W4361960904 hasRelatedWork W2126322332 @default.
• W4361960904 hasRelatedWork W2141521502 @default.
• W4361960904 hasRelatedWork W2318730785 @default.
• W4361960904 hasRelatedWork W2319496893 @default.
• W4361960904 hasRelatedWork W2886854042 @default.
• W4361960904 hasRelatedWork W4205828341 @default.
• W4361960904 hasRelatedWork W4309190708 @default.
• W4361960904 isParatext "false" @default.
• W4361960904 isRetracted "false" @default.
• W4361960904 workType "article" @default.